Proceedings Paper
Photodynamic therapy of malignancies with benzoporphyrin derivative monoacid ring A| Format | Member Price | Non-Member Price |
|---|---|---|
| $17.00 | $21.00 |
Paper Abstract
Benzoporohyrin derivative monoacid ring A (BPD) is a lipophilic photosensitizer with a maximum absorption peak at 690 nm. When liposomally formulated, it distributes in human plasma almost exclusively to the lipoprotein fraction. In experimental animals and humans, it demonstrates good selectivity for tumors as well as other hyperproliferative tissues or cells. In experimental animal tumour models we have found maximum selectivity between tumour and normal surrounding tissue to occur within the first hour following intravenous administration, providing an opportunity for very early PDT following injection. Early clinical trial results from treatment of patients with cutaneous cancerous lesions have shown encouraging efficacy at levels of drug between 0.35 and 0.5 mg/kg. In addition, studies on patients with psoriasis indicate that BPD and light may be used to clear psoriatic plaques.
Paper Details
Date Published: 1 March 1994
PDF: 11 pages
Proc. SPIE 2078, Photodynamic Therapy of Cancer, (1 March 1994); doi: 10.1117/12.168659
Published in SPIE Proceedings Vol. 2078:
Photodynamic Therapy of Cancer
Giulio Jori; Johan Moan; Willem M. Star, Editor(s)
PDF: 11 pages
Proc. SPIE 2078, Photodynamic Therapy of Cancer, (1 March 1994); doi: 10.1117/12.168659
Show Author Affiliations
Julia G. Levy, Quadra Logic Technologies Inc. (Canada)
Elizabeth Waterfield, Quadra Logic Technologies Inc. (Canada)
Anna M. Richter, Quadra Logic Technologies Inc. (Canada)
Claire Smits, Quadra Logic Technologies Inc. (Canada)
Elizabeth Waterfield, Quadra Logic Technologies Inc. (Canada)
Anna M. Richter, Quadra Logic Technologies Inc. (Canada)
Claire Smits, Quadra Logic Technologies Inc. (Canada)
Harvey Lui M.D., Wellman Labs. of Photomedicine/Harvard Medical School (United States)
Univ. of British Columbia and British Columbia Cancer Agency (Canada)
Luciann Hruza, Wellman Labs. of Photomedicine/Harvard Medical School (United States)
R. Rox Anderson M.D., Wellman Labs. of Photomedicine/Harvard Medical School (United States)
Vincent Salvatori, Quadra Logic Technologies Inc. (Canada)
Univ. of British Columbia and British Columbia Cancer Agency (Canada)
Luciann Hruza, Wellman Labs. of Photomedicine/Harvard Medical School (United States)
R. Rox Anderson M.D., Wellman Labs. of Photomedicine/Harvard Medical School (United States)
Vincent Salvatori, Quadra Logic Technologies Inc. (Canada)
Published in SPIE Proceedings Vol. 2078:
Photodynamic Therapy of Cancer
Giulio Jori; Johan Moan; Willem M. Star, Editor(s)
© SPIE. Terms of Use
